Latest update: September 15th, 2013
According to reports on WebMD.com, Swedish pharmaceuticals company Adenovir Pharma is conducting trials on an eye drop called ADP-209 that may finally provide treatment for those suffering from viral conjunctivitis. The treatment targets several adenoviruses which are responsible for most cases of pink eye and creates an artificial surface on the conjunctiva, preventing the virus from binding to the eye and allowing it to be washed away by tears. While the treatment has so far only been tested on animals, results have been promising and Adenovir Pharma is currently working on the next stage of clinical trials.
Conjunctivitis is rarely serious, but complications of pink eye can include corneal inflammation which may affect vision. Symptoms that should be brought to a doctor’s immediate attention include: decreased or blurred vision that does not clear with blinking, continuous or increasing eye pain, a developing sensitivity to light and persistent symptoms that become increasingly more severe or frequent over time.
Sandy Eller is a freelance writer who has written for various websites, newspapers, magazines and private clients in addition to having written song lyrics and scripts for several full scale productions. She can be contacted at firstname.lastname@example.org.Sandy Eller
About the Author: Sandy Eller is a freelance writer who writes for numerous websites, newspapers, magazines and many private clients. She can be contacted at email@example.com.
If you don't see your comment after publishing it, refresh the page.
Our comments section is intended for meaningful responses and debates in a civilized manner. We ask that you respect the fact that we are a religious Jewish website and avoid inappropriate language at all cost.
If you promote any foreign religions, gods or messiahs, lies about Israel, anti-Semitism, or advocate violence (except against terrorists), your permission to comment may be revoked.